Aurenar

Coming – July 22

Transforming Patient Outcomes In The ICU

Date and Time

July 22

12:00 PM ET 9:00 AM PT

Details will be provided upon RSVP approval

About this Event

Each year, a significant portion of the $254B spent annually on ICU care is the result of complications due to inflammation.

Aurenar has developed V-Link, a non-invasive, disposable, in-ear neuromodulation device, similar in size to a Bluetooth earbud. V-Link boosts the body’s natural control of inflammation by activating the vagus nerve with imperceptible and non-invasive stimulation.

V-Link has been successfully demonstrated in multiple randomized controlled clinical pilot studies, showing improved patient outcomes, reduced length of hospital stays, and 20% lower cost of care.

The three initial target indications are Hemorrhagic Stroke, Ischemic Stroke, and Glycemic Control, which create a total addressable market of more than $52B. Long-term applications could extend to outpatient therapy, chronic inflammatory diseases, cognitive enhancement, and even consumer aging, weight loss, and wellness markets.

V-Link is protected by 14 issued patents with 9 more pending. The company is preparing for a De Novo FDA pathway with a pivotal trial across five centers. They are targeting a market launch in Q1 2030.

Join our webinar with Aurenar founder and CEO, Dr. Eric Leuthardt, a professor, neurosurgeon, engineer, and Vice Chancellor at Washington University. He is the founder of multiple companies, holds 600 issued patents with 1,000 pending, and developed the first FDA-approved brain-computer interface for stroke recovery.

Sign Up Today

SHARE THIS EVENT

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts and referenced statistics, contained in this presentation, including statements regarding future company strategy, operations, financial position, revenues, projected costs, plans and objectives of management, will be forward-looking statements.

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.